CasInvent Pharma Secures Next Investment Round with Strong Support from Existing and Local Investors to Advance CK1 Inhibitor Development for Treatment-Resistant Cancer Patients

Funding Rounds

▤ Summary

CasInvent Pharma closed a new investment round with support from existing backers and several local investors in the South Moravian region. The company develops highly selective CK1 inhibitors aimed at treatment-resistant cancers. New investors such as JIC Ventures, Garage Angels members, and Dynumerics joined longstanding supporters including KHAN-I, i&i Prague, and the Holeek Family Foundation. The company says the capital will help move its scientific discoveries closer to clinical translation.

$ Funding

$
Amount None Total raised
□
Date July 2, 2025 Announcement date
◎
Investors Khanu, South Moravian Innovation Center Lead investors
▥
Company casinvent.com Funded company

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies